Greenwich Lifesciences Inc(GLSI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GLSI Greenwich Lifesciences Inc

盘后交易 07-22 17:19:12 EDT

13.27

-1.38

-9.42%

盘后13.41

+0.14+1.06%

16:58 EDT

最高14.81	最低13.00	成交量16.37万
今开14.38	昨收14.65	日振幅12.35%
总市值1.95亿	流通市值1.02亿	总股本1,468万
成交额226.08万	换手率2.14%	流通股本765.31万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GLSI","market":"US","secType":"STK","nameCN":"Greenwich Lifesciences Inc","latestPrice":13.27,"timestamp":1784750400000,"preClose":14.65,"halted":0,"volume":163650,"hourTrading":{"tag":"盘后","latestPrice":13.41,"preClose":13.27,"latestTime":"16:58 EDT","volume":1561,"amount":20724.490059,"timestamp":1784753892353,"change":0.14,"changeRate":0.01055,"amplitude":0.01734},"delay":0,"changeRate":-0.09419795221843008,"floatShares":7653052,"shares":14678200,"eps":-1.604113,"marketStatus":"盘后交易","change":-1.38,"latestTime":"07-22 17:19:12 EDT","open":14.38,"high":14.81,"low":13,"amount":2260787.60145,"amplitude":0.123549,"askPrice":13.41,"askSize":3089,"bidPrice":13.16,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.604113,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784764800000},"marketStatusCode":4,"adr":0,"listingDate":1601006400000,"exchange":"NASDAQ","adjPreClose":14.65,"preHourTrading":{"tag":"盘前","latestPrice":14.5,"preClose":14.65,"latestTime":"09:25 EDT","volume":2244,"amount":32508.071772,"timestamp":1784726759345,"change":-0.15,"changeRate":-0.010239,"amplitude":0.030717},"postHourTrading":{"tag":"盘后","latestPrice":13.41,"preClose":13.27,"latestTime":"16:58 EDT","volume":1561,"amount":20724.490059,"timestamp":1784753892353,"change":0.14,"changeRate":0.01055,"amplitude":0.01734},"volumeRatio":0.514115},"requestUrl":"/m/hq/s/GLSI","defaultTab":"news","newsList":[{"id":"1137171436","title":"Greenwich Lifesciences - Flamingo-01指导委员会支持扩大研究规模并加速患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1137171436","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137171436?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:08","pubTimestamp":1784542094,"startTime":"0","endTime":"0","summary":"Greenwich Lifesciences公司宣布，其Flamingo-01试验的指导委员会已正式批准增加研究规模，并全力推进患者招募加速进程。\n这一决定旨在更快地积累临床数据，为试验的后续推进提供更坚实的支持。加速入组有望缩短整体研究时间线。\n公司对指导委员会的支持表示欢迎，并认为此举将优化试验执行效率。市场密切关注该生物技术公司核心管线的进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175599511","title":"Greenwich Lifesciences 预计2026年第二季度现金消耗率为200万美元；截至2026年6月30日现金余额为890万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175599511","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175599511?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:03","pubTimestamp":1784541793,"startTime":"0","endTime":"0","summary":"Greenwich Lifesciences Inc 公布了其2026年第二季度的财务预期。公司预计该季度的现金消耗率约为200万美元。与此同时，截至2026年6月30日，公司的现金及现金等价物余额为890万美元。这些数据反映了公司在特定时期的资金使用状况与财务流动性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170929019","title":"Greenwich Lifesciences宣布在欧洲获批使用商业化生产的Gp2用于Flamingo-01研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1170929019","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170929019?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:05","pubTimestamp":1783591516,"startTime":"0","endTime":"0","summary":"Greenwich Lifesciences Inc宣布，其商业化生产的Gp2已获得在欧洲用于Flamingo-01研究的批准。这一进展标志着该公司在推进其核心候选产品方面取得了重要的监管里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100764518","title":"Greenwich Lifesciences 在2026年ASCO会议上公布Flamingo-01三期试验开放标签数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1100764518","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100764518?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:17","pubTimestamp":1780316234,"startTime":"0","endTime":"0","summary":"Greenwich Lifesciences 公司近期在2026年美国临床肿瘤学会年会上，公布了其关键性Flamingo-01三期临床试验的开放标签数据。这项研究成果的发布，标志着公司在肿瘤免疫治疗领域取得了新的进展，为后续的临床开发与监管申请提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129440133","title":"Greenwich Lifesciences Inc达成价值高达15.5亿美元现金交易，含首付款与里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1129440133","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129440133?lang=zh_cn&edition=full","pubTime":"2026-05-26 18:46","pubTimestamp":1779792373,"startTime":"0","endTime":"0","summary":"Greenwich Lifesciences Inc (GLSI) 宣布达成一项潜在价值最高可达15.5亿美元的现金交易协议。该交易结构包含首付款以及后续基于研发与商业化进展的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106723359","title":"Greenwich Lifesciences公布Flamingo-01三期临床试验开放标签数据 亮相2026年AACR年会","url":"https://stock-news.laohu8.com/highlight/detail?id=1106723359","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106723359?lang=zh_cn&edition=full","pubTime":"2026-04-20 18:00","pubTimestamp":1776679222,"startTime":"0","endTime":"0","summary":"格林尼治生命科学公司最新披露的Flamingo-01三期临床试验开放标签数据，在2026年美国癌症研究协会年会上正式发布。这项关键性研究数据展现了该公司在肿瘤免疫治疗领域的最新突破。\n临床数据显示，接受GP2肽段疫苗治疗的三阴性乳腺癌患者，在术后辅助治疗中表现出显著的免疫应答。该开放标签扩展研究纳入了已完成标准治疗的早期乳腺癌患者，通过监测GP2特异性T细胞反应评估疫苗疗效。\n研究人员采用ELISPOT检测法测定干扰素-γ分泌水平，发现疫苗接种组较对照组出现明显增强的细胞免疫反应。持续随访数据表明，这种免疫激活效应在强化接种后得以维持，为预防癌症复发提供了新的免疫治疗策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146410981","title":"Greenwich Lifesciences非HLA-A*02亚组初步数据：复发风险降低70-80%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146410981","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146410981?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:05","pubTimestamp":1773828353,"startTime":"0","endTime":"0","summary":"生物制药公司Greenwich Lifesciences Inc近日公布其核心免疫疗法GP2在乳腺癌辅助治疗中的最新分析结果。初步数据显示，在非HLA-A*02基因型患者亚组中，GP2治疗可将乳腺癌复发率显著降低70%-80%。这一数据来自IIb期临床试验的后续分析，涉及约160名已完成标准治疗的HER2/neu阳性乳腺癌患者。GP2是一种靶向HER2/neu蛋白的肽类免疫疗法，通过激活特异性T细胞攻击表达HER2的肿瘤细胞。GP2若在III期临床试验中验证疗效，有望成为首个专注于预防HER2阳性乳腺癌复发的免疫疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100109826","title":"格林威治生命科学股价盘前飙升15%，其GLSI-100药物试验显示乳腺癌复发率降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1100109826","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100109826?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:59","pubTimestamp":1773745195,"startTime":"0","endTime":"0","summary":"格林威治生命科学公司股价在盘前交易中大幅跃升15%。这一强劲表现源于其核心候选药物GLSI-100的临床试验取得了积极结果。数据显示，该药物在降低乳腺癌复发率方面展现出显著潜力。\n市场对此消息反应热烈，投资者信心得到极大提振。新药研发的突破性进展，预示着公司在肿瘤治疗领域的重要突破，也为未来的商业化前景注入了强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144615957","title":"Greenwich Lifesciences公布Flamingo-01开放标签组复发率持续下降的最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1144615957","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144615957?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:01","pubTimestamp":1773741677,"startTime":"0","endTime":"0","summary":"Greenwich Lifesciences Inc（GLSI）近日发布了关于其Flamingo-01临床试验开放标签组的最新进展。数据显示，该组患者的癌症复发率呈现持续下降趋势，进一步验证了试验药物的潜在疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614084901","title":"Greenwich Lifesciences, Inc.盘中异动 早盘股价大涨5.53%报23.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614084901","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614084901?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:43","pubTimestamp":1771944236,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日22时43分，Greenwich Lifesciences, Inc.股票出现异动，股价大幅上涨5.53%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。Greenwich Lifesciences, Inc.公司简介：Greenwich LifeSciences Inc 是一家临床阶段的生物制药公司，专注于其 III 期临床试验 Flamingo-01，该试验正在评估 GLSI-100，是一种预防乳腺癌复发的免疫疗法。GP2 GM-CSF 的组合称为 GLSI-100。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022422435697a6e0ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022422435697a6e0ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611785970","title":"Greenwich Lifesciences, Inc.盘中异动 早盘股价大跌5.84%报26.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611785970","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611785970?lang=zh_cn&edition=full","pubTime":"2026-02-13 00:11","pubTimestamp":1770912700,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日00时11分，Greenwich Lifesciences, Inc.股票出现波动，股价大幅下挫5.84%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体涨幅为0.61%。Greenwich Lifesciences, Inc.公司简介：Greenwich LifeSciences Inc 是一家临床阶段的生物制药公司，专注于其 III 期临床试验 Flamingo-01，该试验正在评估 GLSI-100，是一种预防乳腺癌复发的免疫疗法。GP2 GM-CSF 的组合称为 GLSI-100。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602130011409540f00b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602130011409540f00b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610831389","title":"Greenwich Lifesciences, Inc.盘中异动 股价大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610831389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610831389?lang=zh_cn&edition=full","pubTime":"2026-02-11 02:58","pubTimestamp":1770749939,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日02时58分，Greenwich Lifesciences, Inc.股票出现波动，股价大幅跳水5.21%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Greenwich Lifesciences, Inc.公司简介：Greenwich LifeSciences Inc 是一家临床阶段的生物制药公司，专注于其 III 期临床试验 Flamingo-01，该试验正在评估 GLSI-100，是一种预防乳腺癌复发的免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211025859a494a37a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211025859a494a37a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607988200","title":"Greenwich Lifesciences, Inc.盘中异动 早盘急速拉升5.11%报30.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607988200","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607988200?lang=zh_cn&edition=full","pubTime":"2026-01-29 23:11","pubTimestamp":1769699470,"startTime":"0","endTime":"0","summary":"北京时间2026年01月29日23时11分，Greenwich Lifesciences, Inc.股票出现波动，股价急速拉升5.11%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体涨幅为0.23%。Greenwich Lifesciences, Inc.公司简介：Greenwich LifeSciences Inc 是一家临床阶段的生物制药公司，专注于其 III 期临床试验 Flamingo-01，该试验正在评估 GLSI-100，是一种预防乳腺癌复发的免疫疗法。GP2 GM-CSF 的组合称为 GLSI-100。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129231110a465525e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129231110a465525e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518209140","title":"Greenwich Lifesciences, Inc.盘中异动 下午盘股价大跌5.04%报11.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518209140","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518209140?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:37","pubTimestamp":1741631846,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时37分，Greenwich Lifesciences, Inc.股票出现波动，股价快速下挫5.04%。截至发稿，该股报11.49美元/股，成交量9322股，换手率0.07%，振幅5.21%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体涨幅为0.55%。Greenwich Lifesciences, Inc.公司简介：Greenwich lifessciences Inc 是一家临床阶段的生物制药公司，专注于开发 GP2，这是一种免疫疗法，用于预防已经接受过手术的患者乳腺癌复发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311023726964071c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311023726964071c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517535164","title":"Greenwich Lifesciences, Inc.盘中异动 快速下挫5.44%报11.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517535164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517535164?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:49","pubTimestamp":1741272542,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时49分，Greenwich Lifesciences, Inc.股票出现波动，股价急速下挫5.44%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体跌幅为0.67%。Greenwich Lifesciences, Inc.公司简介：Greenwich lifessciences Inc 是一家临床阶段的生物制药公司，专注于开发 GP2，这是一种免疫疗法，用于预防已经接受过手术的患者乳腺癌复发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224903abeb7cb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224903abeb7cb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516301329","title":"Greenwich Lifesciences, Inc.盘中异动 股价大涨5.29%报12.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301329","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516301329?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:53","pubTimestamp":1740775997,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时53分，Greenwich Lifesciences, Inc.股票出现波动，股价急速上涨5.29%。截至发稿，该股报12.15美元/股，成交量1.4511万股，换手率0.11%，振幅4.85%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。Greenwich Lifesciences, Inc.公司简介：Greenwich lifessciences Inc 是一家临床阶段的生物制药公司，专注于开发 GP2，这是一种免疫疗法，用于预防已经接受过手术的患者乳腺癌复发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010453189896c7eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010453189896c7eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506306788","title":"Greenwich Lifesciences, Inc.盘中异动 早盘股价大涨5.04%报13.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506306788","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506306788?lang=zh_cn&edition=full","pubTime":"2025-01-27 23:24","pubTimestamp":1737991477,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日23时24分，Greenwich Lifesciences, Inc.股票出现异动，股价急速上涨5.04%。截至发稿，该股报13.75美元/股，成交量1.1902万股，换手率0.09%，振幅4.20%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体涨幅为1.32%。Greenwich Lifesciences, Inc.公司简介：Greenwich lifessciences Inc 是一家临床阶段的生物制药公司，专注于开发 GP2，这是一种免疫疗法，用于预防已经接受过手术的患者乳腺癌复发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127232437abba6aed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127232437abba6aed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505720299","title":"Greenwich Lifesciences, Inc.盘中异动 早盘股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505720299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505720299?lang=zh_cn&edition=full","pubTime":"2025-01-23 00:12","pubTimestamp":1737562326,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日00时12分，Greenwich Lifesciences, Inc.股票出现异动，股价大幅上涨5.26%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Greenwich Lifesciences, Inc.公司简介：Greenwich lifessciences Inc 是一家临床阶段的生物制药公司，专注于开发 GP2，这是一种免疫疗法，用于预防已经接受过手术的患者乳腺癌复发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123001207a22bc844&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123001207a22bc844&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505191202","title":"Greenwich Lifesciences, Inc.盘中异动 股价大跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505191202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505191202?lang=zh_cn&edition=full","pubTime":"2025-01-22 02:03","pubTimestamp":1737482583,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日02时03分，Greenwich Lifesciences, Inc.股票出现波动，股价大幅下挫5.28%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体涨幅为2.22%。Greenwich Lifesciences, Inc.公司简介：Greenwich lifessciences Inc 是一家临床阶段的生物制药公司，专注于开发 GP2，这是一种免疫疗法，用于预防已经接受过手术的患者乳腺癌复发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122020303960bddc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122020303960bddc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503477583","title":"Greenwich Lifesciences, Inc.盘中异动 早盘股价大跌7.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503477583","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503477583?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:32","pubTimestamp":1736778726,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时32分，Greenwich Lifesciences, Inc.股票出现波动，股价急速下跌7.11%。Greenwich Lifesciences, Inc.股票所在的生物技术行业中，整体跌幅为0.89%。Greenwich Lifesciences, Inc.公司简介：Greenwich lifessciences Inc 是一家临床阶段的生物制药公司，专注于开发 GP2，这是一种免疫疗法，用于预防已经接受过手术的患者乳腺癌复发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223206aba930af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223206aba930af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.greenwichlifesciences.com","stockEarnings":[{"period":"1week","weight":-0.2294},{"period":"1month","weight":-0.3734},{"period":"3month","weight":-0.4126},{"period":"6month","weight":-0.3782},{"period":"1year","weight":0.2457},{"period":"ytd","weight":-0.3027}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Greenwich LifeSciences, Inc.成立于2006年8月29日，是特拉华州的一家公司。该公司是一家生物制药公司，正在开发GP2，这是一种旨在预防术后乳腺癌复发的免疫疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.082906},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.00815},{"month":3,"riseRate":0.5,"avgChangeRate":0.044197},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.141916},{"month":5,"riseRate":0.5,"avgChangeRate":-0.011066},{"month":6,"riseRate":0.5,"avgChangeRate":0.028818},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.074688},{"month":8,"riseRate":0.6,"avgChangeRate":0.020316},{"month":9,"riseRate":0.2,"avgChangeRate":-0.041624},{"month":10,"riseRate":0,"avgChangeRate":-0.089083},{"month":11,"riseRate":0.666667,"avgChangeRate":0.225666},{"month":12,"riseRate":0.5,"avgChangeRate":1.139783}],"exchange":"NASDAQ","name":"Greenwich Lifesciences Inc","nameEN":"Greenwich Lifesciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Greenwich Lifesciences Inc(GLSI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Greenwich Lifesciences Inc(GLSI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Greenwich Lifesciences Inc,GLSI,Greenwich Lifesciences Inc股票,Greenwich Lifesciences Inc股票老虎,Greenwich Lifesciences Inc股票老虎国际,Greenwich Lifesciences Inc行情,Greenwich Lifesciences Inc股票行情,Greenwich Lifesciences Inc股价,Greenwich Lifesciences Inc股市,Greenwich Lifesciences Inc股票价格,Greenwich Lifesciences Inc股票交易,Greenwich Lifesciences Inc股票购买,Greenwich Lifesciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Greenwich Lifesciences Inc(GLSI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Greenwich Lifesciences Inc(GLSI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}